Cancer immunotherapy
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Recent scientific advances have expanded our understanding of the immune system and its response to malignant cells. The clinical goal of tumour immunotherapy is to provide either passive or active immunity against malignancies by harnessing the immune system to target tumours. Monoclonal antibodies, cytokines, cellular immunotherapy, and vaccines have increasingly become successful therapeutic agents for the treatment of solid and haematological cancers in preclinical models, clinical trials, and practice. In this article, we review recent advances in the immunotherapy of cancer, focusing on new strategies and future perspectives as well as on clinical trials attempting to enhance the efficacy of immunotherapeutic modalities and translate this knowledge into effective cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669 · cited 1×
“Tregs are a subset of CD4+ T cells that are known to inhibit both the activation and proliferation of cytotoxic and helper T cells, and they are likely to play a major role in the induction of functional immune tolerance to tumours often observed in cancer patients.(194) Other regulatory CD4+ T-cell subsets likely tar…”
BackgroundT-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · cited 1×
“This type of immunotherapy has the advantage that one can administer extremely high numbers of non-modified or genetically engineered lymphocytes with high avidity for tumour antigens.(9) Furthermore, adoptive cellular immunotherapy (ACT) can include both CD4 and CD8 T cells capable of recognizing tumour antigens and…”
BackgroundCD1d-Restricted and TCR-Mediated Activation of V α 14 NKT Cells by Glycosylceramides
Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., et al. (1997) · Science · doi:10.1126/science.278.5343.1626 · Cited by 2,400
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389 · cited 3×
“Adoptive transfer of autologous tumour-specific T cells, as initially reported in the late 1980s, has been shown to reproducibly mediate the destruction of bulky tumours in a respectable percentage of the patients treated.179 This approach is mainly based on growing tumour-infiltrating lymphocytes ex vivo from surgica…”
BackgroundInfluentialImmunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008 · cited 1×
“One way to improve the induction phase is to block the negative regulators of the activation of effector T cells.(132) Antibodies against one such molecule, CTLA-4, are being evaluated in clinical trials.”
BackgroundHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940 · cited 1×
“In a murine model, antiCTLA-4 mAb has demonstrated anti-tumour activity in moderately antigenic and highly immunogenic tumours.(75) Anti-CTLA-4 mAb alone is not sufficient to alter the growth of poorly immunogenic tumours, such as MC38.”
BackgroundCerwenka, A., Baron, J. L., & Lanier, L. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201238598 · Cited by 606
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594 · cited 1×
“Attempts at immunotherapy of cancer have included therapeutic vaccination with recombinant viral vectors encoding tumour-associated antigens,(126) recombinant proteins with appropriate adjuvants,(127) antigen-loaded DC,(128) DNA encoding tumour-associated antigens,(5) and synthetic peptides.(129) However, apart from i…”
ResultRibas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591 · cited 1×
“Tremelimumab induced durable objective responses with low-grade toxicities when used as second-line monotherapy in a phase I study with melanoma patients treated with single, escalating doses.(80) Subsequently, in a phase II trial, patients with advanced melanoma randomly were assigned to receive either 10 mg/kg treme…”
MethodAntonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444 · cited 2×
“Antonia et al.150 vaccinated 29 patients with extensive stage small cell lung cancer with a DC-based p53 vaccine.”
BackgroundRosenberg, S. A., Sportès, C., Ahmadzadeh, M., Fry, T. J., Ngo, L. T., Schwarz, S. L., Stetler-Stevenson, M., Morton, K. E., Mavroukakis, S. A., Morre, M., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000210386.55951.c2 · Cited by 443 · cited 1×
“Two phase I/II trials utilizing recombinant IL-7 have been completed in patients with cancer.(30,31) There was no toxicity while dramatic increases in total body CD4+ and CD8+ T cells were observed with no selective increase in Tregs.”
MethodOffner, S., Hofmeister, R., Romaniuk, A., Kufer, P., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.03.007 · Cited by 365
Hoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, C., Prang, N., & Baeuerle, P. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20908 · Cited by 344
BiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260 · cited 2×
“T cells to lyse tumour cells.(10) One scFv interacts with epitopes on tumour cells, whereas the other scFv binds an epitope on the TCR/CD3 complex of T cells.”
BackgroundBrischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.034 · Cited by 256
Dreier, T., Baeuerle, P. A., Fichtner, I., Grün, M., Schlereth, B., Lorenczewski, G., Kufer, P., Lutterbüse, R., Riethmüller, G., Gjorstrup, P., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.8.4397 · Cited by 191
Schlereth, B., Fichtner, I., Lorenczewski, G., Kleindienst, P., Brischwein, K., da Silva, A., Kufer, P., Lutterbuese, R., Junghahn, I., Kasimir-Bauer, S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2637 · Cited by 132
Interleukin 21: a cytokine/cytokine receptor system that has come of age
Leonard, W. J., Zeng, R., & Spolski, R. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0308149 · Cited by 122 · cited 1×
“IL-21 belongs to the -chain family of cytokines (together with IL-2, IL-4, IL-7, IL-9, and IL-15) and it is primarily produced by CD4+ T cells.(54,55) It induces differentiation of pro-inflammatory CD4+ Th17 cells, stimulates memory and naïve CD8+ T-cell expansion synergistically with IL-7 or IL-15, and improves degr…”
Background
Cited by
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Metadata
- Authors
- Baxevanis, C. N., Perez, S. A., & Papamichail, M.
- Venue
- Critical Reviews in Clinical Laboratory Sciences
- Publisher
- Informa UK Limited
- Published
- 2009-08
- Volume
- 46
- Issue
- 4
- Pages
- 167-189
- ISSN
- 1040-8363 (ISSN-L)
- 1549-781X
- OpenAlex
- W4211140292
- Cited by
- 175
- References
- 22
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.